1、novotech-JUNE 14,2024Oesophageal CancerGlobal Clinical Trial Landscape(2024)Globally,Oeso-phageal Cancer is the 11th most diagnosed cancer and the 7th most leading cause of cancer mortalityThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be r

2、eproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright st

3、atement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its righ

4、ts.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?Asia had the highest incidence cases and accounted for nearly 70%of the global incidence cases of OCEurope had the second highest incidence,with over 53,500 casesNorth America had more than 21,800 cases,followed b

5、y rest of the world(ROW)The OC treatment market ofers diverse products by companies including Advanz Pharma Corp.Ltd,BeiGene Ltd.,InnoKeys Pte.Ltd.and Simcere Pharmaceutical Group Ltd Multiple ongoing Phase III trials demonstrate continued eforts to enhance OC treatment through antibody,small molecu

6、le,bispecific or multispecific antibody and peptide vaccine therapiesTRIAL CONTRIBUTIONS5%ROW49%NORTH AMERICA&EUROPE46%ASIA-PACIFICGlobally,OC accounted for nearly 511,000 new cases in 2022Countries like Mainland China,the United States,South Korea,and Spain emerged as top locations for conducting t